Released May 10, 2012, after the close
10-Q filed May 11, 2012, 41 days after period end · 0001019687-12-001718
Q1 2012 · 10-Q
Revenue$6.07M$6.07M +1.1% vs Q1 2011−0.6% vs Q4 2011
Net Income-$1.05M-$1.05M N/M vs Q1 2011N/M vs Q4 2011
EPS Diluted-$0.02-$0.02 N/M vs Q1 2011N/M vs Q4 2011
Operating Income-$997,000N/M
Operating Cash Flow$255,000−71.8%
Free Cash Flowderived-$150,000N/M
Margins · derived
Operating margin-16.4%−7.8 pt vs Q1 2011
Net margin-17.2%−7.9 pt vs Q1 2011
What the release said
The release
Same quarter
| Metric | Q1 2012 | Q1 2011 |
|---|---|---|
| Revenue | $6.07M | $6.00M |
| Net Income | -$1.05M | -$559.00K |
| EPS Diluted | -$0.02 | -$0.01 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ernexa Therapeutics Inc. · CIK 748592 · Engraved from SEC EDGAR